𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

✍ Scribed by R. BRUNO; P. SACCHI; C. SCAGNOLARI; F. TORRIANI; L. MAIOCCHI; S. PATRUNO; F. BELLOMI; G. FILICE; G. ANTONELLI

Book ID
108605023
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
531 KB
Volume
26
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Proceed with caution: Peginterferon alph
Proceed with caution: Peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials
✍ David Kershenobich; Linda Muñoz; René Malé; Jesús Gaytan; Francisco Sánchez 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB

We read with great interest the article by Cavazza et al., 1 who demonstrated that an advanced histological stage was the only risk factor associated with the development of hepatocellular carcinoma (HCC) in patients with primary biliary cirrhosis (PBC) from two European centers. Similar results wer

Treatment of insulin resistance with met
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin
✍ Manuel Romero-Gómez; Moisés Diago; Raúl J. Andrade; José L. Calleja; Javier Salm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 1 views

Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12

Peginterferon alpha-2a is associated wit
Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials
✍ Tahany Awad; Kristian Thorlund; Goran Hauser; Davor Stimac; Mahasen Mabrouk; Chr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 1 views

A combination of weekly pegylated interferon (peginterferon) alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines. It is not established which of the two licensed products (peginterferon alpha-2a or peginterferon alfa-2b)

Peginterferon alfa-2b and weight-based o
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial
✍ Ira M. Jacobson; Robert S. Brown Jr; Bradley Freilich; Nezam Afdhal; Paul Y. Kwo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

Clifford A. Brass, 15 and the WIN-R Study Group This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in adults with

Peginterferon alfa-2b plus ribavirin tre
Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C
✍ Stefan Wirth; Heidrun Pieper-Boustani; Thomas Lang; Antje Ballauff; Ulrike Kullm 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

Peginterferon plus ribavirin is standard therapy for adults with chronic hepatitis C. As no data are available for children, the aim of the study was to evaluate the efficacy and tolerability of peginterferon alfa-2b in combination with ribavirin in chronically infected children. Genotypes, alanine